This study is in progress, not accepting new patients
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Summary
- Eligibility
- for people ages 16-80 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- Related Info
- ID
- NCT03398148
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- About 1554 people participating
- Last Updated